Premium
Treatment of high‐risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide
Author(s) -
Theodore Christine,
Azab Mohamed,
Droz JeanPierre,
Assouline Alain,
George Martine,
Piot Gilles,
Bellet Dominique,
Michel Guy,
Amiel JeanLouis
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891101)64:9<1824::aid-cncr2820640911>3.0.co;2-y
Subject(s) - etoposide , medicine , regimen , gestational trophoblastic disease , chemotherapy , cisplatin , combination chemotherapy , surgery , oncology , pregnancy , gestation , biology , genetics
The authors have treated 22 patients with high‐risk gestational trophoblastic disease (GTD) by cisplatin‐etoposide‐containing combinations. Sixteen patients were treated with dactinomycin, platinum, and etoposide combination (APE regimen) and six patients had platinum and etoposide combination (PE regimen). Fourteen patients were treated for resistant or relapsing GTD after first‐line therapy, and eight patients initially. All 22 patients were high risk according to the World Health Organization prognostic score values. Sustained complete remission was achieved in 19 patients (86%). All eight patients who received treatment as initial therapy were cured (100%) whereas only 11 patients were cured among the 14 patients who failed prior chemotherapy (78%). Hematologic and renal toxicities were limited and no treatment‐related deaths occurred in this group of patients. Cisplatin and etoposide could be more widely used in chemotherapeutic combinations for high‐risk gestational trophoblastic disease.